Previously, we reported that the paralogous zinc-finger proteins -CTCF and brother of the regulator of imprinted sites (BORIS), directly contribute to transcriptional regulation of NY-ESO-1 in lung cancer cells. To further examine mechanisms that mediate expression of this cancer-testis gene, we performed software-guided analysis of the NY-ESO-1 promoter region, which revealed several potential Sp1-binding motifs. Sequential 5-aza-2 0 deoxycytidine/depsipeptide FK228 treatment markedly induced BORIS expression and enhanced nuclear translocation of Sp1 in lung cancer cells. Transient transfection assays using promoter-reporter constructs, as well as gel-shift and chromatin immunoprecipitation experiments revealed that NY-ESO-1 promoter activity coincided with occupancy of the proximal Sp1-binding site in lung cancer cells. Mutations within the Sp1 recognition sequence specifically eliminated binding of Sp1 to this motif in vitro, and markedly diminished NY-ESO-1 promoter activity in vivo. siRNA-mediated inhibition of Sp1 expression decreased NY-ESO-1 promoter activity, whereas knock down of CTCF expression augmented NY-ESO-1 transcription in lung cancer cells. Co-immunoprecipitation experiments indicated that Sp1 physically interacts with BORIS but not with CTCF in vivo. Collectively, these findings suggest that BORIS recruits Sp1 to mediate de-repression of NY-ESO-1 during pulmonary carcinogenesis.
Introduction
Cancer-testis antigens (CTA) constitute a unique and growing class of germ cell-related proteins that are aberrantly expressed in a variety of human malignancies, and are recognized by cytolytic T lymphocytes (CTL) from cancer patients (Simpson et al., 2005) . During recent years, the CTAs have emerged as attractive targets for cancer immunotherapy. Of particular interest in this regard, are CTAs encoded on the X chromosome (CT-X), such as NY-ESO-1, which elicits cellular, as well as humoral immunity in approximately 50% of patients whose tumors express this cytoplasmic protein (Gnjatic et al., 2006) .
Recent studies indicate that the nuclear proteins CTCF and BORIS (Brother of the Regulator of Imprinted Sites) may contribute to regulation of NY-ESO-1 expression during pulmonary carcinogenesis (Hong et al., 2005) . CTCF is a ubiquitous DNA-binding protein bearing a central 11 zinc (Zn)-finger region that contributes to formation of chromatin insulator/boundaries, X chromosome inactivation, reading of geneimprinting marks, and regulation of a variety of genes mediating cell cycle progression and apoptosis (reviewed by Ohlsson et al. (2001) ; Klenova et al. (2002) ). BORIS exhibits considerable homology to CTCF in the central 11 Zn-finger DNA-binding domain, but not in the NH 2 -and COOH-terminal regions that constitute approximately two-thirds of the full-length amino-acid sequences of these proteins (Loukinov et al., 2002) . Thus, whereas CTCF and BORIS apparently recognize the same DNA-binding sequences, these transcription factors may exhibit significant differences regarding recruitment of functional partners (reviewed in Klenova et al. (2002) ). Unlike CTCF, BORIS is not expressed in normal somatic cells (Klenova et al., 2002; Loukinov et al., 2002) . In male germ cells, transient expression of BORIS coincides with a marked decrease in CTCF expression, erasure of global DNA methylation patterns, and upregulation of CT genes (Loukinov et al., 2002) .
Recently, we reported that BORIS is activated during pulmonary carcinogenesis, and that BORIS expression coincides with de-repression of NY-ESO-1 (Hong et al., 2005) . In addition, we have demonstrated that BORIS as well as NY-ESO-1 expression can be induced in cultured lung cancer cells (but not normal human bronchial epithelial (NHBE) cells) following exposure to the DNA-demethylating agent 5-aza-2 0 deoxycytidine (DAC), the histone deacetylase (HDAC) inhibitor Depsipeptide FK228 (DP), or sequential DAC/DP. Furthermore, we have shown that a CTCF-to-BORISshift in occupancy of the NY-ESO-1 promoter coincides with de-repression of this CT gene in lung cancer cells (Hong et al., 2005) ; a similar phenomenon was observed for activation of MAGE-A1 in these cells (Vatolin et al., 2005) .
Whereas our published data (Hong et al., 2005) , as well as additional recent studies (James et al., 2006) indicate that de-repression of NY-ESO-1 coincides with alterations of chromatin structure within the promoter region of this CT gene, it is conceivable that BORIS/ CTCF-mediated regulation of NY-ESO-1 may entail mechanisms other than those directly involving DNA methylation or modifications of the histone code. For instance, the functional NY-ESO-1 promoter region contains multiple trans-acting factor-binding sites including a characteristic specificity protein 1 (Sp1) motif downstream from the putative BORIS/CTCF recognition sequence (CCCTC). Sp1 is a member of a family of transcription factors that bind GC/GT-rich promoter elements via three C 2 H 2 -type zinc fingers present within their C-terminal domains (Suske, 1999; Safe and Abdelrahim, 2005) . There is growing evidence that Sp1 is overexpressed in human malignancies (Hosoi et al., 2004; Yao et al., 2004) , and that Sp1 modulates growth and metastasis of cancer cells, in part, by regulating expression of a variety of cell-cycle-related genes, as well as vascular endothelial growth factor (Pore et al., 2004; Safe and Abdelrahim, 2005) . Of particular interest in this regard, are recent data indicating that HDAC inhibitors such as DP induce p21 expression via activation of Sp1 (Nguyen et al., 2004) . The present study was undertaken to investigate the functional relevance of Sp1 with regard to CTCF/BORIS-mediated regulation of NY-ESO-1 expression in lung cancer cells.
Results

Role of Sp1 in regulating NY-ESO-1 expression in lung cancer cells
Computerized analysis of the NY-ESO-1 promoter region revealed several potential Sp1 recognition sites, including one located approximately 250 bp downstream from the CCCTC motif, the putative CTCF/BORIS consensus sequence. In order to examine if Sp1 contributed to inducible as well as constitutive expression of NY-ESO-1, we focused our analysis on two lung cancer lines (Calu-6 and H1299) as well as cultured NHBE cells. As shown in Table 1 , these cells exhibit significantly different basal as well as inducible levels of BORIS, CTCF and NY-ESO-1 expression. Inhibition of DNA methyltransferase (DNMT) 1 as well as DNMT3b appears necessary for maximal induction of BORIS and NY-ESO-1 by chromatin remodeling agents.
Initial experiments were undertaken to ascertain the effects of mithramycin A, a compound that competitively inhibits binding of Sp1 to target GC boxes (Albertini et al., 2006) on NY-ESO-1 promoter activity in Calu-6 cells. As shown in Figure 1a , mithramycin A (2 Â 10 À6 M) reduced the activity of pGL3/NY762 to 30% of its original activity; in fact, luciferase activity of the promoter-reporter construct in sequential DAC/ DP-treated Calu-6 cells following mithramycin exposure was nearly as low as that observed in vector controltransfected Calu-6 cells, which were exposed to chromatin remodeling agents. The role of Sp1 in regulating NY-ESO-1 promoter activity was further examined using siRNA targeting Sp1 expression in H1299 cells. As shown in Figure 1b , dose-dependent inhibition of Sp1 expression coincided with a dramatic decrease in NY-ESO-1 promoter activity.
Cellular localization of Sp1 in response to DAC/DP treatment Western blot experiments were performed to investigate if induction of NY-ESO-1 by sequential DAC/DP treatment was related to increased Sp1 protein levels, or was the result of re-localization of this transcription factor. As shown in Figure 2 , in the absence of drug treatment, Sp1 was primarily detected in cytoplasmic extracts from Calu-6 as well as H1299 cells. Following sequential DAC/DP treatment, Sp1 was detected predominantly in nuclear extracts. Sequential DAC/DP treatment had no apparent effect on total Sp1 protein levels.
Functional mapping of the region required for Sp1-mediated regulation of NY-ESO-1 Six NY-ESO-1 promoter/luciferase constructs, with successive 100 bp-deletions at the 5 0 end were cloned; schematic representations of the constructs are depicted in Figure 3a . Following transfection into H1299 cells, significant reduction in the relative luciferase activity (RLA) was observed commencing with pGL3/NY562, The Sp1 site is crucial for NY-ESO-1 promoter activity Two promoter-reporter constructs (pGL3/NY762M2 and pGL3/NY762M3) bearing point mutations within the Sp1-binding site of the NY-ESO-1 promoter, which were identical to those depicted in Figure 4a were cloned using site-specific mutagenesis techniques. The activities of the mutated NY-ESO-1 promoters were investigated using reporter transient transfection assays. Consistent with results of EMSA described above, the RLA of M2, normalized for the Renase internal control, was markedly reduced in untreated H1299 cells ( Figure 5a ); luciferase activity of the M3 construct was also reduced albeit to a lesser extent compared to the unmutated construct (WT) (Figure 5a ). Additional experiments indicated that when plasmid constructs bearing Sp1 mutations were transfected into Calu-6 cells, the mutated NY-ESO-1 promoter exhibited considerable loss of responsiveness to sequential DAC/
Relative Luc activity Dynamic regulation of NY-ESO-1 Y Kang et al DP treatment; in contrast, luciferase activity of the intact NY-ESO-1 promoter was significantly enhanced by drug treatment (Figure 5b ). Decreased luciferase activities of the mutated NY-ESO-1 promoter constructs were also observed in untreated Calu-6 cells ( Figure 5b ).
Endogenous as well as exogenous BORIS physically interact with Sp1
Co-immunoprecipitation experiments were performed to evaluate interaction of BORIS, CTCF and Sp1 in lung cancer cells. As shown in Figure 6 , Sp1 coimmunoprecipitated with BORIS ( Figure 6a ) but not with CTCF from nuclear extracts prepared from H1299 cells. To determine whether exogenous BORIS physically interacts with endogenous Sp1 independent of its binding to the NY-ESO-1 promoter, co-immunoprecipitation experiments were performed using nuclear extracts prepared from Calu-6 transfected with the BORIS expression vector pcDNA4-BORIS/cMyc-His; Western blot analysis confirmed expression of the fusion protein only in extracts from pcDNA4-BORIS/ cMyc-His-transfected cells (Figure 6c, upper panel) . cMyc antibody co-immunoprecipitated Sp1 from nuclear extracts prepared from Calu-6 cells transfected with the fusion construct, but not control cells (Figure 6c, lower panel) . In all indicated experiments, immunoprecipitates with non-specific antibody did not yield any specific, detectable interactions (data not shown).
WT:
CAAGCTGGCATTG CGGCCACCTTCCGGCCCGGGCTCTCTTGGGGAGGGGCGGGGTTGGTGAGA ACCGGTCACGTGCTCCGGGGCTCACTCGGGGTCTCCC
M1:
CAAGCTGGCATTG CGGCCACCTTCCGGCCCGGGCTCTCTTGGGGAGGTTCGAAGTTGGTGAGAA CCGGTCACGTGCTCCGGGGCTCACTCGGGGTCTCCC
M2:
CAAGCTGGCATTG CGGCCACCTTCCGGCCCGGGCTCTCTTGGGGAGGGGCAT GGTTGGTGAGA ACCGGTCACGTGCTCCGGGGCTCACTCGGGGTCTCCC
M3:
CAAGCTGGCATTG CGGCCACCTTCCGGCCCGGGCTCTCTTGGGGAGAAGCGGGGTTGGTGAGA ACCGGTCACGTGCTCCGGGGCTCACTCGGGGTCTCCC
M4:
CAAGCTGGCATTG Bisulfite sequencing and ChIP techniques were used to examine DNA methylation and histone acetylation status of the Sp1-binding region within the NY-ESO-1 promoter. The Sp1 site lies within a recently described CpG island (James et al., 2006) . Although several CpG dinucleotides are within or adjacent to the Sp1-binding site, no consistent methylation profile coincided with NY-ESO-1 expression in normal or malignant cells (Figure 7b ; left panel). Subsequent ChIP analysis revealed that DP mediated an obvious increase in acetylation of histone H3 associated with the Sp1 recognition sequence within the NY-ESO-1 promoter (Figure 7b, right panel) . Consistent with these observations, acetylation status of histone H3 associated with the Sp1 recognition sequence within the NY-ESO-1 promoter in H1299 cells was markedly enhanced relative to NHBE cells.
Role of CTCF in regulating NY-ESO-1 promoter activity in lung cancer cells
Additional efforts focused on dissecting the role of CTCF in regulating NY-ESO-1 promoter activity in lung cancer cells. Endogenous CTCF levels were knocked down by siRNA techniques; reduced CTCF expression was verified by Western blots (Figure 8a ). Transient transfection assays using the pGL3/NY762 construct revealed that knock-down of CTCF expression coincided with an increase of NY-ESO-1 promoter activity in Calu-6 cells treated with DAC/DP (Figure 8a ). Co-immunoprecipitation experiments were then performed to examine whether a decrease in CTCF expression affected interaction between BORIS and Sp1 in H1299 and Calu-6 cells. As shown in Figure 8b , Western blot analysis revealed relatively stable BORIS protein levels following knock down of CTCF (Figure 8b) . Interestingly, when CTCF protein was depleted, significantly more Sp1 was found to be associated with BORIS in DAC/DP-treated Calu-6 as well as untreated H1299 cells (Figure 8c) .
Discussion
Approximately, 50% of cancer-testis antigens, including NY-ESO-1 are encoded on the X chromosome. CT-X genes are normally expressed in proliferating male germ cells (spermatogonia), and typically comprise extended families associated with inverted DNA repeats. The remaining C-T antigens are encoded by loci dispersed throughout the autosomes, which typically are not associated with extended families or inverted repetitive DNA sequences; these non-X CT genes tend to be expressed during later stages of germ cell differentiation (i.e., spermatocytes) (Zendman et al., 2003; Simpson et al., 2005) . There is growing evidence that the CT-X genes are more frequently activated in cancer cells, 
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and that particular gene families are simultaneously de-repressed in a tumor-specific manner. For instance, NY-ESO-1 is often activated in association with MAGE-A1 and MAGE-3 in lung cancer cells (Schrump and Nguyen, 2005) . Our recent observations regarding activation of BORIS in lung cancer cells (Hong et al., 2005) are consistent with the notion that de-repression of CT-X genes during malignant transformation recapitulates epigenetic reprogramming in germ cells (Zendman et al., 2003; Simpson et al., 2005) . Our unpublished experiments indicate that there are numerous BORIS alternative transcripts, which are expressed in lung cancer cells, and that CT-X expression profiles may coincide with expression of particular splice variants. These observations could account, at least in part, for the preferential de-repression of CT-X genes in small cell vs non-small cell lung cancers, and the complexity of the DNA methylation paradox in these malignancies. In the present study, we provide evidence that BORISmediated recruitment of Sp1 is an important mechanism by which NY-ESO-1 is de-repressed in lung cancer cells. Consistent with our data are observations that mutations within the Sp1 recognition sequence of the MAGE-A4 promoter markedly inhibit transcription of this CT-X gene (De Plaen et al., 1997) . Interestingly, several Sp1 alternative transcripts are differentially expressed during murine spermatogenesis (Persengiev et al., 1996; Thomas et al., 2005) . Presently, it is not clear if activation of alternative Sp1 transcripts contributes to the DNA methylation paradox in human cancer cells.
Sp1 activates promoters via recruitment of additional regulatory proteins, leading to formation of a functional transcriptional machinery (Suzuki et al., 2000; Safe and Abdelrahim, 2005; Hung et al., 2006) . Nuclear translocation of Sp1 appears to contribute significantly to BORIS-mediated induction of NY-ESO-1 in cancer cells following sequential DAC/DP exposure. Although interaction with BORIS appears critical, additional mechanisms could facilitate recruitment of Sp1 to the NY-ESO-1 promoter. In general, epigenetic regulation of gene expression requires coordinated changes in DNA methylation as well as the histone code, which collectively enhance or inhibit binding of transcription factors, RNA pol II and TFIIB (Zhang et al., 2005) . Although NY-ESO-1 expression did not appear to coincide with methylation status of the Sp1-recognition site, our current data do not exclude the possibility that demethylation of other regions within the NY-ESO-1 promoter facilitates Sp1-mediated induction of this CT gene either by enhancing expression and/or recruitment of additional co-factors, or RNA pol II activity. Furthermore, it is conceivable that chromatin remodeling secondary to binding of BORIS upstream and/ or hyperacetylation of core histones contributes to enhanced Sp1 interaction with the NY-ESO-1 promoter (Husmann et al., 2000) . In addition, post-translational modifications of Sp1 may also augment interaction of this transcription factor with the NY-ESO-1 promoter. Several recent studies indicate that HDAC inhibitors mediate acetylation of Sp1, and enhance binding of Sp1 to target recognition sequences (Ryu et al., 2003; Huang et al., 2005) . Finally, our data do not exclude the possibility that micro-RNAs induced by HDAC inhibition (Scott et al., 2006) augment expression of NY-ESO-1. These issues are a focus of ongoing experiments in our laboratory. 
Cells were exposed to normal media for 96 h, or DAC (0.1 mmol/l) for 72 h (fresh DAC added every 24 h), followed by exposure to DP (25 ng/ml Â 6 h), and normal media Â 18 h. Cells were harvested for analysis at the 96-h time point unless otherwise specified.
Subcellular fractionation and Western blotting
Fractionation of cultured cells was performed using the nuclear extract kit (Pierce, Rockford, IL, USA), following vendor's instructions. Western blot analysis of Sp1 and CTCF protein levels was performed as described in Supplementary materials.
Plasmid constructs
The NY-ESO-1 luciferase reporter construct, designated as pGL3/ESO-762, which contains 762 bp (À207 to À968) fragment of the 5 0 -flanking region of NY-ESO-1 gene was cloned as reported previously (Hong et al., 2005) . The plasmid containing the full-length BORIS coding cDNA and cMyc tag, pcDNA/BORIS-cMyc was made by cloning BORIS cDNA into the pcDNA4/myc-His B vector (Invitrogen, Carlsbad, CA, USA). Integrity of the fusion construct was verified by DNA sequencing; expression of recombinant protein following transient transfection was confirmed by Western blot analysis.
Mutagenesis of Sp1 recognition site on NY-ESO-1 promoter DNA Mutations of the Sp1-binding site within the NY-ESO-1 promoter were performed with reference to the results from gel shifting experiments (as described in the following section). Two mutated versions of plasmid pGL3/NY762 containing point mutations within the Sp1 recognition site were constructed using the QuikChange mutagenesis kit (Stratagene, La Jolla, CA, USA). In addition, six truncated versions of plasmid pGL3/ESO-762 were prepared by cloning serially shortened PCR products into Mlu-XhoI sites within pGL3 basic vector, each with a deletion of approximately 100 bp from the previous one at the 5 0 end of the 762 bp fragment. Details regarding construction and nomenclature of these mutants are described in Supplementary materials.
Transfections and Reporter Assays
All transfections were performed using LipofectAMINE 2000CD (Invitrogen), and luciferase assays were carried out using the Dual-Luc Reporter Assay System (Roche, Nutley, NJ, USA) according to the respective vendor instructions as previously reported (Hong et al., 2005) . Detailed methods for these transfection experiments are submitted as Supplementary materials.
Nuclear protein extraction
Techniques used for extraction of nuclei from subconfluent cells are submitted as Supplementary materials.
Immunoprecipitation and immunoblotting
Techniques used for immunoprecipitation and immunoblotting are described in detail in Supplementary materials.
siRNA construction and transfection
The siRNAs against Sp1 and CTCF were purchased from Pharmacon (Chicago, IL, USA). RNAiFect transfection reagent was purchased from Qiagen (Valencia, CA, USA). Subconfluent cells were transfected according to vendor instructions, and harvested 48 h later for analysis of target gene knock down. Details of the siRNA transfection techniques are submitted as Supplementary materials.
Bioinformatics analysis
Software programs used to predict transcription factorbinding motifs on the NY-ESO-1 762-bp promoter included MOTIF Search (http://motif.genome. jp) with a cutoff score of 100 employing the vertebrates matrix group and Proscan (Version 1.7) (http://thr.cit.nih.gov/cgi-bin/molbio/proscan), with promoter score of 61.76 and promoter cutoff of 53.
Electrophoretic mobility shift Assay
Wild type and four oligonucleotide probes containing base substitutions in the Sp1 consensus sequence were designed. The primer sequences used to generate these oligo probes, as well as methods for EMSA are described in detail in Supplementary materials.
ChIP and bisulfite sequencing analysis of the NY-ESO-1 promoter Details pertaining to evaluation of the Sp1 region of the NY-ESO-1 promoter via these techniques are submitted as Supplementary materials. Dynamic regulation of NY-ESO-1 Y Kang et al
